Alembic Pharmaceuticals gets USFDA nod for generic hypertension treatment capsules

Alembic Pharmaceuticals Ltd has secured final approval from the USFDA for its generic Diltiazem Hydrochloride extended-release capsules. These capsules, available in strengths of 120 mg to 360 mg, are designed to treat hypertension and manage angina. This approval grants Alembic access to an estimated market valued at USD 105.3 million annually.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yXOLMB6
via IFTTT